New Era of Preventing End-Stage Kidney Disease Act
Sponsored By: Representative Bilirakis
Introduced
Summary
Preventing end-stage kidney disease by creating NIDDK Centers of Excellence that fund research, expand provider and public education, and reach rural and underserved communities to better diagnose and treat rare kidney diseases.
Show full summary
- Researchers and clinicians: Establishes NIDDK Centers of Excellence on Rare Kidney Disease Research and funds grants and cooperative agreements to study causes, symptoms, diagnosis, progression, and treatments, including genotype‑phenotype relationships. It bars use of QALYs, DALYs, or similar measures that discriminate against people with disabilities in value assessments.
- Patients and families: Permits centers to cover patient care costs needed for research and to provide education on diagnosis, routine urinalysis, genetic testing, renal diet, and mental and emotional health resources. The bill emphasizes outreach and information programs for rural and underserved communities and people diagnosed with rare kidney diseases.
- Health systems and federal coordination: Supports clinical training, continuing education, and demonstration projects for diagnostic, prevention, control, and treatment methods and requires coordination with other NIH institutes and the FDA. Each center may receive up to 5 years of support with possible 5‑year extensions under peer review, and the bill authorizes $6 million per year for FY2026–2030 to carry out these activities.
*If enacted, this bill would authorize $6 million per year for FY2026–2030, increasing federal spending by about $30 million over that five-year period.*
Bill Overview
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Medicare tests to delay dialysis
If enacted, HHS would run Medicare experiments to test treatments for rare kidney disease. The focus would be on options that delay or avoid dialysis or transplant. HHS would also study how to raise public awareness of rare kidney disease. A report to Congress would be due within 24 months of enactment.
New centers for rare kidney disease
If enacted, NIH could fund regional Centers of Excellence for rare kidney disease. Centers could cover patient care needed for research and provide training and outreach, including urinalysis and genetic testing. Outreach would target rural and underserved communities and include renal diet and family support resources. Each center could get support for up to 5 years, with possible 5-year extensions after review. The bill would authorize $6 million each year for 2026–2030 and require research on genes and disease, while barring QALY/DALY-style measures.
National study on kidney testing
If enacted, HHS would study testing, prevention, precision medicine, and care for rare kidney disease. The study would review urinalysis, biopsies, genetic tests like APOL1, insurance and counseling access, and treatment patterns across Medicare, Medicaid, and private plans. HHS would consult with providers, patient groups, payors, and public health and coordinate with NIH, CMS, HRSA, and CMMI. A report to Congress would be due within 18 months. The bill would authorize $1 million each year for 2026–2030.
More kidney training for doctors
If enacted, grants could fund nephrology fellowships, including stipends for postgraduate trainees. Training would focus on preventing, diagnosing, and treating rare kidney disease, including APOL1 risks, and improving care for affected communities. The bill would also add kidney disease to required topics in primary care training programs.
Sponsors & CoSponsors
Sponsor
Bilirakis
FL • R
Cosponsors
Sewell
AL • D
Sponsored 2/24/2025
Miller (WV)
WV • R
Sponsored 2/24/2025
Peters
CA • D
Sponsored 2/24/2025
Balderson
OH • R
Sponsored 2/24/2025
Tonko
NY • D
Sponsored 2/24/2025
Schneider
IL • D
Sponsored 2/24/2025
Davis (IL)
IL • D
Sponsored 2/24/2025
Lieu
CA • D
Sponsored 3/3/2025
Dunn (FL)
FL • R
Sponsored 3/10/2025
Fitzpatrick
PA • R
Sponsored 3/11/2025
Crenshaw
TX • R
Sponsored 3/14/2025
Del. Norton, Eleanor Holmes [D-DC-At Large]
DC • D
Sponsored 5/7/2025
Suozzi
NY • D
Sponsored 5/14/2025
Brownley
CA • D
Sponsored 5/19/2025
Obernolte
CA • R
Sponsored 5/19/2025
Lawler
NY • R
Sponsored 5/19/2025
Castor (FL)
FL • D
Sponsored 6/3/2025
Davis (NC)
NC • D
Sponsored 6/6/2025
Wilson (SC)
SC • R
Sponsored 6/23/2025
Tlaib
MI • D
Sponsored 6/30/2025
Johnson (GA)
GA • D
Sponsored 7/23/2025
Ryan
NY • D
Sponsored 7/23/2025
Nadler
NY • D
Sponsored 7/25/2025
Garbarino
NY • R
Sponsored 7/25/2025
Bishop
GA • D
Sponsored 7/25/2025
Correa
CA • D
Sponsored 7/29/2025
McGovern
MA • D
Sponsored 7/29/2025
Jackson (IL)
IL • D
Sponsored 8/1/2025
Crow
CO • D
Sponsored 8/5/2025
Soto
FL • D
Sponsored 8/12/2025
Lofgren
CA • D
Sponsored 8/12/2025
Green, Al (TX)
TX • D
Sponsored 8/12/2025
Ross
NC • D
Sponsored 8/12/2025
Menendez
NJ • D
Sponsored 8/19/2025
McBride
DE • D
Sponsored 8/26/2025
Kim
CA • R
Sponsored 9/3/2025
Ocasio-Cortez
NY • D
Sponsored 9/3/2025
Vindman
VA • D
Sponsored 9/3/2025
Van Drew
NJ • R
Sponsored 9/30/2025
Ivey
MD • D
Sponsored 9/30/2025
Stevens
MI • D
Sponsored 10/21/2025
Carey
OH • R
Sponsored 10/21/2025
Flood
NE • R
Sponsored 11/4/2025
Cuellar
TX • D
Sponsored 11/4/2025
Vasquez
NM • D
Sponsored 12/17/2025
Kiggans (VA)
VA • R
Sponsored 2/26/2026
Lee (NV)
NV • D
Sponsored 2/26/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govRelated Bills
HR842 — Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Would expand Medicare to cover multi-cancer early detection screening tests. It defines eligible tests as certain FDA-cleared or approved genomic blood tests or comparable biological-sample tests and directs the Secretary to use the national coverage determinations process to decide when they are covered.
HR1262 — Mikaela Naylon Give Kids a Chance Act
Speeds and strengthens pediatric cancer drug development. It expands which cancer products companies must study in children, reshapes organ transplant network governance and fees, and adds new FDA international and transparency steps. - Children with cancer and researchers: Requires pediatric studies that produce clinically meaningful data on dosing, safety, and early effectiveness and widens the kinds of drug combinations studied. It also sets aside $25 million for pediatric drug studies in each of fiscal years 2026, 2027, and 2028. - Transplant patients and transplant network members: Changes Organ Procurement and Transplantation Network governance and financing by allowing quarterly registration fees, requiring those fees fund OPTN operations, improving electronic health record integration, and calling for a GAO review within two years. - FDA partners and drug makers: Creates an Abraham Accords Office to boost regulatory coordination and technical assistance abroad, and forces more transparency during generic (ANDA) reviews about whether generics are qualitatively and quantitatively the same as listed drugs. It also raises the Medicare Improvement Fund amount from $1.4 billion to $2.6 billion. Increases federal outlays by roughly $1.3 billion, driven by a $1.2 billion boost to the Medicare Improvement Fund and $75 million for pediatric studies, adding to federal spending.
HR2102 — Major Richard Star Act
Establishes concurrent receipt for retirees with combat-related disabilities. This bill would let eligible retirees receive both military retired pay and veterans' disability compensation for the same months without the offset rules that currently reduce payments. - Families of disabled retirees: Veterans with combat-related disabilities would receive both retired pay and VA disability compensation for the same months, increasing their monthly household income. - Defense and VA payment rules: The bill would amend 10 U.S.C. 1413a and 10 U.S.C. 1414 to exempt retired pay from reductions under 38 U.S.C. 5304 and 5305 and add a clear monthly no-offset rule. - Implementation and technical changes: It renames and updates chapter sections, adjusts cross-references, and applies to payments beginning the first month after enactment.
HR3514 — Improving Seniors’ Timely Access to Care Act of 2025
Standardize prior authorization in Medicare Advantage plans to make approvals faster and more transparent for beneficiaries and providers. The bill would require plans that use prior authorization to adopt a secure electronic PA program, publish plan-level PA data, and follow federal timeframes and enrollee protections.
HR909 — Crime Victims Fund Stabilization Act of 2025
Would make the False Claims Act apply to deposits to the Crime Victims Fund through FY2029. It would also require an Inspector General audit that sets the audit's scope, timing, and recipients, and the measure is titled the Crime Victims Fund Stabilization Act of 2025. - Entities that make deposits to the Crime Victims Fund would be subject to the False Claims Act (31 U.S.C. 3729–3731) for deposits from enactment through FY2029. - An Inspector General audit would examine the Crime Victims Fund and the bill would set the audit's scope, timing, and who receives the report.
HR1993 — 25th Anniversary of 9/11 Commemorative Coin Act
Would create two commemorative coins marking the 25th anniversary of the September 11 attacks and raise funds for the National September 11 Memorial and Museum. The bill would direct the Secretary of the Treasury to mint up to 50,000 $5 gold coins and up to 400,000 $1 silver coins. Each coin would be at least 90 percent precious metal, meet specific weight and size specs, be legal tender, and be offered in uncirculated and proof qualities. Designs would honor victims, first responders, and survivors and include required inscriptions such as Liberty, In God We Trust, United States of America, E Pluribus Unum, and 25th Anniversary, with at least one coin bearing the inscription “Never Forget.” Sales would include a $35 surcharge on each gold coin and a $10 surcharge on each silver coin to support the museum. Issuance would be limited to the one-year period beginning January 1, 2027, and coins would be struck at the U.S. Mint in West Point to the greatest extent possible, with the Citizens Coinage Advisory Committee and the Commission of Fine Arts consulted on designs. It would be structured to result in no net cost to the federal government.
Take It Personal
Get Your Personalized Policy View
Create a free account to save research, track policy impacts, and unlock your personalized versions of these pages.
Already have an account? Sign in